English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
Bright China 2025: Airdoc PBM Vision Rehabilitation Device Clinical Research Data Release
Nov 11, 2025 09:22 HKT
Bright China 2025:鹰瞳PBM视力康复仪临床研究数据发布
Nov 11, 2025 09:20 HKT
Bright China 2025:鷹瞳PBM視力康復儀臨牀研究數據發佈
Nov 11, 2025 09:20 HKT
全球首创抗炎代谢调节剂HTD1801完成2型糖尿病III期临床研究 展现持续52周的综合获益与安全性优势
Oct 31, 2025 08:30 HKT
全球首創抗炎代謝調節劑HTD1801完成2型糖尿病III期臨床研究 展現持續52周的綜合獲益與安全性優勢
Oct 31, 2025 08:30 HKT
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
Oct 30, 2025 20:00 HKT
康哲药业(867.HK;8A8.SG)长效抗IL-4Rα人源化单抗注射液MG-K10特应性皮炎适应症中国NDA已获受理
Oct 30, 2025 18:27 HKT
康哲藥業(867.HK;8A8.SG)長效抗IL-4Rα人源化單抗注射液MG-K10特應性皮炎適應症中國NDA已獲受理
Oct 30, 2025 18:27 HKT
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
Oct 30, 2025 16:48 HKT
云顶新耀与Visara签订协议 将在大中华区及其他亚洲市场开发及商业化VIS-101
Oct 30, 2025 16:36 HKT
雲頂新耀與Visara簽訂協議 將在大中華區及其他亞洲市場開發及商業化VIS-101
Oct 30, 2025 16:36 HKT
康哲藥業(867.HK; 8A8.SG)簽訂眼科藥物諾適得(R)與倍優適(R)經銷協議
Oct 28, 2025 18:22 HKT
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R)
Oct 27, 2025 22:00 HKT
康哲药业(867.HK; 8A8.SG)签订眼科药物诺适得(R)与倍优适(R)经销协议
Oct 27, 2025 18:29 HKT
云顶新耀召开公司发展战略交流会 加强全球布局 实现跨越式发展战略
Oct 22, 2025 13:53 HKT
雲頂新耀召開公司發展戰略交流會 加強全球佈局 實現跨越式發展戰略
Oct 22, 2025 13:53 HKT
Owkin 推出 K Pro:首个由生物推理模型驱动的生物制药智能 AI 协作助手
Oct 16, 2025 14:00 HKT
Owkin 推出 K Pro:首個由生物推理模型驅動的生物製藥智能 AI 協作助手
Oct 16, 2025 14:00 HKT
Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models
Oct 16, 2025 13:00 HKT
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
Oct 14, 2025 17:38 HKT
Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: